FDA OKs Merck's Recarbrio For Hospital And Ventilator Associated Bacterial Pneumonia

The U.S. Food and Drug Administration approved Merck & Co. Inc.'s combination antibiotic Recarbrio for the expanded indication in the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). The drug had received initial approval in the U.S. in July 2019 to treat patients with complicated urinary tract infections and complicated intra-abdominal infecti

from RTT - Biotech https://ift.tt/30cV5m6
via IFTTT